- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07392892
Eine Studie zum Erlernen des Studienmedikaments PF-08634404 in Kombination mit Chemotherapie bei gastroösophagealem Krebs
EINE INTERVENTIONELLE PHASE-2/3-STUDIE ZU PF-08634404 IN KOMBINATION MIT CHEMOTHERAPIE BEI BEHANDLUNGSNAÏVEN TEILNEHMERN MIT LOKAL FORTGESCHRITTENEM ODER METASTASIERTEM MAGEN-, GASTROÖSOPHAGEALEM ÜBERGANGS- ODER ÖSOPHAGEALEM ADENOKARZINOM
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-Mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- Rekrutierung
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Rekrutierung
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200031
- Rekrutierung
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Rekrutierung
- Sichuan Cancer hospital
-
-
-
-
-
Paris, Frankreich, 75015
- Rekrutierung
- Hôpital Européen Georges Pompidou
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 4941492
- Rekrutierung
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israel, 5265601
- Rekrutierung
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israel, 6423906
- Rekrutierung
- Sourasky Medical Center
-
-
-
-
-
Milan, Italien, 20141
- Rekrutierung
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekrutierung
- Aichi Cancer Center
-
-
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Noch keine Rekrutierung
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Rekrutierung
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Puerto Rico, 00674
- Rekrutierung
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spanien, 08035
- Rekrutierung
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28041
- Rekrutierung
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Spanien, 32005
- Noch keine Rekrutierung
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Tainan, Taiwan, 704302
- Rekrutierung
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Rekrutierung
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Rekrutierung
- Taipei Veterans General Hospital
-
-
-
-
California
-
Atascadero, California, Vereinigte Staaten, 93422
- Rekrutierung
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, Vereinigte Staaten, 91505
- Rekrutierung
- UCLA Hematology/Oncology - Burbank
-
Encino, California, Vereinigte Staaten, 91436
- Rekrutierung
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, Vereinigte Staaten, 90292
- Rekrutierung
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, Vereinigte Staaten, 91326
- Rekrutierung
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, Vereinigte Staaten, 94158
- Noch keine Rekrutierung
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, Vereinigte Staaten, 94158
- Noch keine Rekrutierung
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, Vereinigte Staaten, 93401
- Rekrutierung
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, Vereinigte Staaten, 93101
- Rekrutierung
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, Vereinigte Staaten, 90404
- Rekrutierung
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, Vereinigte Staaten, 80303
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, Vereinigte Staaten, 80112
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Vereinigte Staaten, 80907
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Vereinigte Staaten, 80923
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Vereinigte Staaten, 80220
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, Vereinigte Staaten, 80113
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, Vereinigte Staaten, 80228
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, Vereinigte Staaten, 80120
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, Vereinigte Staaten, 80504
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, Vereinigte Staaten, 81003
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, Vereinigte Staaten, 80260
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, Vereinigte Staaten, 32117
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
Fleming Island, Florida, Vereinigte Staaten, 32003
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, Vereinigte Staaten, 33410
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
Sebring, Florida, Vereinigte Staaten, 33870
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
Wellington, Florida, Vereinigte Staaten, 33414
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
West Palm Beach, Florida, Vereinigte Staaten, 33401
- Noch keine Rekrutierung
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, Vereinigte Staaten, 60005
- Rekrutierung
- Illinois Cancer Specialists
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Rekrutierung
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, Vereinigte Staaten, 60631
- Rekrutierung
- Illinois Cancer Specialists
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Rekrutierung
- Illinois CancerCare - Galesburg
-
Niles, Illinois, Vereinigte Staaten, 60714
- Rekrutierung
- Illinois Cancer Specialists
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Rekrutierung
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Rekrutierung
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Rekrutierung
- Illinois CancerCare, P.C.
-
Peru, Illinois, Vereinigte Staaten, 61354
- Rekrutierung
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, Vereinigte Staaten, 61571
- Rekrutierung
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, Vereinigte Staaten, 21401
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, Vereinigte Staaten, 20817
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, Vereinigte Staaten, 20613
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, Vereinigte Staaten, 21044
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, Vereinigte Staaten, 20876
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, Vereinigte Staaten, 20774
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, Vereinigte Staaten, 20850
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, Vereinigte Staaten, 20904
- Rekrutierung
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Regional Medical Center
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Health Medical Oncology
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Noch keine Rekrutierung
- Atlantic Health System
-
Summit, New Jersey, Vereinigte Staaten, 07901
- Noch keine Rekrutierung
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, Vereinigte Staaten, 11101
- Rekrutierung
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, Vereinigte Staaten, 11101
- Rekrutierung
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, Vereinigte Staaten, 10022
- Rekrutierung
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45245
- Rekrutierung
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Rekrutierung
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Vereinigte Staaten, 45211
- Rekrutierung
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, Vereinigte Staaten, 45014
- Rekrutierung
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, Vereinigte Staaten, 19020
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, Vereinigte Staaten, 18901
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, Vereinigte Staaten, 19044
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, Vereinigte Staaten, 19047
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, Vereinigte Staaten, 19063
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, Vereinigte Staaten, 18960
- Rekrutierung
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- Rekrutierung
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, Vereinigte Staaten, 75063
- Rekrutierung
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, Vereinigte Staaten, 22201
- Rekrutierung
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, Vereinigte Staaten, 23320
- Rekrutierung
- Virginia Oncology Associates
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, Vereinigte Staaten, 23666
- Rekrutierung
- Virginia Oncology Associates
-
Manassas, Virginia, Vereinigte Staaten, 20110
- Rekrutierung
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, Vereinigte Staaten, 23606
- Rekrutierung
- Virginia Oncology Associates
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Rekrutierung
- Virginia Oncology Associates
-
Reston, Virginia, Vereinigte Staaten, 20190
- Rekrutierung
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, Vereinigte Staaten, 23456
- Rekrutierung
- Virginia Oncology Associates
-
Woodbridge, Virginia, Vereinigte Staaten, 22191
- Rekrutierung
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98195
- Rekrutierung
- University of Washington Medical Center
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- Harborview Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andere Namen:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Experimental: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andere Namen:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Aktiver Komparator: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Zeitfenster: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Zeitfenster: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Zeitfenster: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 2: Inzidenz von Anti-Drug-Antikörpern (ADA) gegen PF-08634404
Zeitfenster: Etwa 21 Monate
|
Etwa 21 Monate
|
|
|
Phase 3: Inzidenz von ADA gegen PF-08634404
Zeitfenster: Ungefähr 21 Monate
|
Ungefähr 21 Monate
|
|
|
Phase 3: Veränderung gegenüber dem Ausgangswert im Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) Gesamtscore
Zeitfenster: Etwa 4 Jahre
|
Etwa 4 Jahre
|
|
|
Phase 3: Zeit bis zur definitiven Verschlechterung des FACT-Ga-Gesamtscores
Zeitfenster: Etwa 4 Jahre
|
Etwa 4 Jahre
|
|
|
Phase 3: Zeit bis zur definitiven Verschlechterung im Gastric Cancer Subscale (GaCS)-Score
Zeitfenster: Etwa 4 Jahre
|
Etwa 4 Jahre
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Zeitfenster: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Zeitfenster: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Zeitfenster: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Zeitfenster: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Zeitfenster: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Zeitfenster: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Zeitfenster: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Zeitfenster: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Zeitfenster: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Zeitfenster: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Pfizer CT.gov Call Center, Pfizer
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Magenerkrankungen
- Magenneoplasmen
- Adenokarzinom der Speiseröhre
- Aminosäuren, Peptide und Proteine
- Proteine
- Therapeutika
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Nivolumab
- Arzneimitteltherapie
Andere Studien-ID-Nummern
- C6461016
- 2025-524717-86-00 (Registrierungskennung: CTIS (EU))
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .